Presented by Dr Sheela Rao (Royal Marsden Hospital NHS Foundation Trust, Surrey, UK)
Dr Sheela Rao, consultant medical oncologist at the Royal Marsden Hospital in London, presented an update on recent advances in the management of advanced anal cancer, highlighting how the field has evolved over the past year. Following the presentation of pivotal data at ESMO, a new standard of care has now been established: the combination of carboplatin and paclitaxel with the PD-1 inhibitor retifanlimab. The full results, recently published in The Lancet, confirmed the earlier findings—showing that the addition of retifanlimab doubles response rates, significantly extends duration of response, and improves both progression-free and overall survival compared with chemotherapy alone. Importantly, the regimen was well tolerated, consolidating its role as first-line therapy for metastatic or unresectable anal cancer.
Further studies are ongoing to refine and expand upon these results. A U.S. phase III trial is evaluating a similar combination—carboplatin, paclitaxel, and nivolumab—with PFS as the primary endpoint and a longer course of immunotherapy. This will provide important comparative and confirmatory data.
Attention is now turning to the post-progression setting, as more patients will have received immunotherapy in the frontline. Promising investigational strategies include HPV-targeted T-cell vaccines, potentially in combination with checkpoint inhibitors, as well as ADCs. These approaches aim to overcome resistance mechanisms and extend the benefit beyond first-line therapy.
Dr Rao also noted the value of translational research embedded in the retifanlimab trial, which includes a comprehensive collection of tumour biopsies and blood samples. This represents the largest molecular and immunologic dataset in this rare cancer to date and is expected to yield critical insights into biomarkers of response and resistance. Molecular profiling remains a key focus, as many anal cancers harbour PIK3CA mutations, though their clinical relevance is not yet clear. Understanding these pathways could open the door to targeted therapies for immunotherapy-refractory disease.
In parallel, interest is growing in localised anal cancer, where immunotherapy may soon move into the adjuvant setting. A major U.S. study has completed accrual, testing the addition of immunotherapy after standard chemoradiation, with PFS as the primary endpoint. If positive, this could reshape management even in earlier-stage disease.
Overall, the anal cancer treatment landscape is undergoing rapid transformation, driven by the integration of immunotherapy and molecular research. Dr Rao emphasised that after decades of limited progress, the field is finally entering an era of innovation and expansion, with multiple trials now exploring new combinations and settings. The coming years are expected to refine the role of immunotherapy further and translate translational discoveries into more durable and personalised treatment options for patients with this rare malignancy.
References:
Rao S. et al., The Lancet, Volume 405, Issue 10495, 2144 – 2152
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in